MedTrace Logo

Study of the Combination of CM082 With Everolimus in Patients With mRCC

NCT02577458 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-01-10

No results posted yet for this study

Summary

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination with Everolimus in Chinese Patients With Advanced Renal Cell Carcinoma.

Conditions

  • Renal Cell Carcinoma Recurrent

Interventions

DRUG

CM082

CM082 tablets taken orally once a day on 28-day cycles

DRUG

Everolimus

Everolimus tablets taken orally once a day on 28-day cycles

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • AnewPharma

    lead INDUSTRY

Principal Investigators

  • Jun Guo, M.D · Peking University Cancer Hospital & Institute

  • Xinan Sheng, M.D · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-03-31
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02577458 on ClinicalTrials.gov